Yayoi Fujioka

Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors

Hiroshi Sootome, Hidenori Fujita, Kenjiro Ito et al. · Cancer Research · 2020 · 184 citations · Full text

The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked <i>In Vivo</i> Antitumor Properties and a Favorable Tolerability Profile

Hidenori Fujita, Kazutaka Miyadera, Masanori Kato et al. · Molecular Cancer Therapeutics · 2013 · 37 citations

Acquired resistance to trastuzumab/pertuzumab or to T‐DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728

Hiroki Irie, Rumi Kawabata, Yayoi Fujioka et al. · Cancer Science · 2020 · 37 citations · Full text

Breast Oncology, Immunology, Immunotherapy +20

Abstract A270: TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities.

Hiroaki Ochiiwa, Hidenori Fujita, Kimihiro Itoh et al. · Molecular Cancer Therapeutics · 2013 · 28 citations

Abstract A270, Pathology, Cellular Phosphorylation +16

Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of nuclear factor κB pathways

Hiromi Muraoka, Chihoko Yoshimura, Rumi Kawabata et al. · Cancer Science · 2019 · 24 citations · Full text